In my May 19 post, I disclose a new Thermo Fisher Scientific (TMO) position in the FFJ Portfolio. On May 24, I published a brief post in which I disclose an increase in my TMO exposure. I now hold 75 shares in a 'Core' account at an average cost of ~$509.61 and 52 shares in [...]
I last reviewed CME Group (CME) in this November 14, 2022 post at which time the most recently available financial information was for Q3 and YTD2022. At the time of that post, my CME exposure consisted of 382 CME shares in a 'Core' account and 321 shares in a 'Side' account within the FFJ Portfolio. [...]
Fortive (FTV) was spun off from Danaher (DHR) on July 2, 2016; my recent DHR post is accessible here. I last reviewed FTV in this October 29, 2022 post at which time Q3 and YTD2022 results had just been released. While I wanted to add to my exposure, I had depleted my liquidity because we [...]
I last reviewed Danaher (DHR) in this October 21, 2022 post at which time I held 285 DHR shares in a 'Core' account in the FFJ Portfolio. In a brief January 6, 2023 post, I disclose the purchase of an additional 50 shares @ ~$246.18/share thereby increasing my exposure to 335 shares. I subsequently acquired: [...]
Some investors think the demise of oil and gas producers is on the horizon as the transition toward more environmentally friendly forms of energy gathers momentum. I completely disagree. The future supply of several metals and minerals is critical for the success of the energy transition. Any transition depends on the sustainable supply of metals [...]
I last reviewed S&P Global (SPGI) in my February 10, 2023 post at which time I passed on acquiring additional shares in the hope of being able to acquire additional shares in the future at a more favourable valuation. SPGI has now released its Q2 and YTD2023 results on July 27. This is an opportune [...]
RTX Corporation - Geared Turbofan Engine (GTF) I last reviewed RTX Corporation (RTX) (formerly Raytheon Technologies Corporation) in this January 25, 2023 post at which time it had just released its Q4 and FY2022 results and FY2023 outlook. Although I considered RTX's valuation fair, I refrained from adding to my exposure. I hoped [...]
Alternative asset exposure (eg. private equity, private debt, hedge funds, real estate, commodities, structured products, venture capital) can produce attractive long-term investment returns. Directly investing in alternative assets, however, is beyond my risk tolerance. This is why a portion of my alternative asset exposure is through Blackstone (BX). I last reviewed Blackstone (BX) in [...]
I last reviewed Intuitive Surgical (ISRG) in this April 19, 2023 post at which time it had just released Q1 2023 results. With the release of Q2 and YTD2023 results following the July 20, 2023 market close, I revisit this existing holding. Overview Please refer to the company's website and 'Item 1 - Business' in [...]
My last Genuine Parts (GPC) post was on March 23, 2023 post following my review of GPC's 2023 Investor Day material. Fast forward to July 20 at which time GPC released Q2 and YTD2023 financial results and FY2023 guidance. The tumble in GPC's share price following the release of these results has piqued my interest [...]